The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

被引：0
|
作者：
Gonchigdash, Chinbat [1 ]
Purevsuren, Baljinnyam [1 ]
Tungalag, Saruul [1 ]
Tungalagchimeg, Erdenechimeg [1 ]
Norov, Oyundelger [1 ]
机构：
[1] First Cent Hosp Mongolia, Ulaanbaatar, Mongolia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MPN; ruxolitinib; polycythemia vera; hydroxyurea;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-374
引用
收藏
页码：S430 / S430
页数：1
相关论文
共 50 条
  • [1] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera: A Systematic Review and Meta-Analysis
    Mora, Maria Meritxell Roca
    Guimaraes, Catharina Ribeiro
    Afzal, Farhan
    Godoi, Amanda
    Valenzuela, Andres
    BLOOD, 2023, 142
  • [2] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
    Harrison, Claire N.
    Nangalia, Jyoti
    Boucher, Rebecca
    Jackson, Aimee
    Yap, Christina
    O'Sullivan, Jennifer
    Fox, Sonia
    Ailts, Isaak
    Dueck, Amylou C.
    Geyer, Holly L.
    Mesa, Ruben A.
    Dunn, William G.
    Nadezhdin, Eugene
    Curto-Garcia, Natalia
    Green, Anna
    Wilkins, Bridget
    Coppell, Jason
    Laurie, John
    Garg, Mamta
    Ewing, Joanne
    Knapper, Steven
    Crowe, Josephine
    Chen, Frederick
    Koutsavlis, Ioannis
    Godfrey, Anna
    Arami, Siamak
    Drummond, Mark
    Byrne, Jennifer
    Clark, Fiona
    Mead-Harvey, Carolyn
    Baxter, Elizabeth Joanna
    McMullin, Mary Frances
    Mead, Adam J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3534 - +
  • [3] Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy
    Verstovsek, Srdan
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Miller, Carole
    Naim, Ahmad B.
    Paranagama, Dilan C.
    Habr, Dany
    Vannucchi, Alessandro M.
    LEUKEMIA RESEARCH, 2017, 56 : 52 - 59
  • [4] Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    Vannucchi, Alessandro M.
    Kiladjian, Jean Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Mesa, Ruben
    He, Shui
    Jones, Mark M.
    Garrett, William
    Li, Jingjin
    Pirron, Ulrich
    Habr, Dany
    Verstovsek, Srdan
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05): : 426 - 435
  • [5] Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    Hasselbalch, Hans C.
    Bjorn, Mads E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17): : 1670 - 1670
  • [6] THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB
    Melikyan, A. L.
    Subortseva, I. N.
    Gilyazitdinova, E. A.
    Kovrigina, A. M.
    Sudarikov, A. B.
    Abdullaev, A. O.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (04): : 229 - 232
  • [7] Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Kirito, Keita
    Besses, Carlos
    Hino, Masayuki
    Moiraghi, Beatriz
    Miller, Carole B.
    Cazzola, Mario
    Rosti, Vittorio
    Blau, Igor
    Mesa, Ruben
    Jones, Mark M.
    Zhen, Huiling
    Li, Jingjin
    Francillard, Nathalie
    Habr, Dany
    Kiladjian, Jean-Jacques
    HAEMATOLOGICA, 2016, 101 (07) : 821 - 829
  • [8] RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA: 80-WEEK FOLLOW-UP FROM THE RESPONSE TRIAL
    Kiladjian, J. -J.
    Vannucchi, A. M.
    Griesshammer, M.
    Masszi, T.
    Durrant, S.
    Passamonti, F.
    Harrison, C. N.
    Pane, F.
    Zachee, P.
    Kirito, K.
    Cazzola, M.
    Besses, C.
    Blau, I.
    Mesa, R.
    Jones, M. M.
    He, S.
    Zhen, H.
    Li, J.
    Francillard, N.
    Habr, D.
    Verstovsek, S.
    HAEMATOLOGICA, 2015, 100 : 161 - 161
  • [9] Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results
    Mesa, Ruben
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    He, Shui
    Jones, Mark M.
    Parasuraman, Shreekant
    Li, Jingjin
    Cote, Isabelle
    Habr, Dany
    Vannucchi, Alessandro M.
    BLOOD, 2014, 124 (21)
  • [10] Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta-analysis
    Mora, M. Meritxell Roca
    Afzal, Farhan
    Guimaraes, Catharina Ribeiro
    Cunha, Luisa Marin
    Godoi, Amanda
    Marcolin, Patricia
    Valenzuela, S. Andres
    APMIS, 2024, 132 (11) : 775 - 786
12345